These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11565461)

  • 21. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control.
    Perkins JM; Davis SN
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):147-52. PubMed ID: 18316950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypertension and diabetes: role of the renin-angiotensin system.
    Jandeleit-Dahm K; Cooper ME
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):469-90, vii. PubMed ID: 16959581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Arterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy.
    Manolis AJ; Iraklianou S; Pittaras A; Zaris M; Tsioufis K; Psaltiras G; Psomali D; Foussas S; Gavras I; Gavras H
    Am J Hypertens; 2005 Jan; 18(1):18-22. PubMed ID: 15691612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy.
    Seki N; Hashimoto N; Suzuki Y; Yagui K; Saito Y
    Diabetes Res Clin Pract; 2006 May; 72(2):135-41. PubMed ID: 16290123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renin-Angiotensin-Aldosterone system inhibition in prevention of diabetes mellitus.
    Bălută M; Vintilă V; Vintilă M
    Rom J Intern Med; 2004; 42(2):277-88. PubMed ID: 15529618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renin-angiotensin blockade in diabetic retinopathy.
    Ghattas A; Lip PL; Lip GY
    Int J Clin Pract; 2011 Feb; 65(2):113-6. PubMed ID: 21235693
    [No Abstract]   [Full Text] [Related]  

  • 30. The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease.
    Weir MR
    Postgrad Med; 2009 Jan; 121(1):96-103. PubMed ID: 19179817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The renin angiotensin system as a therapeutic target to prevent diabetes and its complications.
    Vijayaraghavan K; Deedwania PC
    Cardiol Clin; 2005 May; 23(2):165-83. PubMed ID: 15694745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Late diagnosis. Only after myocardial infarction is diabetes discovered].
    MMW Fortschr Med; 2003 Feb; 145(9):56. PubMed ID: 12666536
    [No Abstract]   [Full Text] [Related]  

  • 33. ACE inhibitors and risk of hypoglycemia in people with diabetes.
    Chaturvedi N; Fuller JH
    Diabetes Care; 1998 Mar; 21(3):470-2. PubMed ID: 9540046
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients.
    Böger CA; Götz AK; Krüger B; Hösl M; Schmitz G; Riegger GA; Krämer BK
    Eur J Med Res; 2005 Apr; 10(4):161-8. PubMed ID: 15946912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of severe hypoglycemia in diabetes patients taking ACE inhibitors.
    Strachan MW; Frier BM
    Diabetes Care; 1998 Mar; 21(3):470; author reply 471-2. PubMed ID: 9540045
    [No Abstract]   [Full Text] [Related]  

  • 37. Angiotensin II receptor blockers: current perspective.
    Agrawal V; Manohar G; Kasliwal RR
    J Assoc Physicians India; 2003 Jul; 51():706-13. PubMed ID: 14621043
    [No Abstract]   [Full Text] [Related]  

  • 38. Treating diabetic nephropathy: unfinished success is not failure.
    Lewis J
    Clin J Am Soc Nephrol; 2007 May; 2(3):407-9. PubMed ID: 17699442
    [No Abstract]   [Full Text] [Related]  

  • 39. Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes.
    Tikellis C; Cooper ME; Thomas MC
    Int J Biochem Cell Biol; 2006; 38(5-6):737-51. PubMed ID: 16198140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hypertension in patients with diabetes].
    Poulsen PL; Hansen KW; Gaede PH; Rossing P
    Ugeskr Laeger; 2009 Jun; 171(24):2031-4. PubMed ID: 19523370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.